{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2020"],"condition":["HER2-positive Colorectal Cancer","Endometrial Cancer","Gastrointestinal Cancer","Head and Neck Cancer","Colorectal Cancer","Endometrial Neoplasms","Breast Cancer","HER2-positive Breast Cancer","Non-Small Cell Lung Cancer","HER2-positive Solid Tumors","Gastric Cancer","Colorectal Neoplasms","HER2-positive Gastroesophageal Cancer","HER2-positive Endometrial Cancer"],"disease":["Endometrial Cancer","Gastrointestinal Cancer","Colorectal Cancer","Endometrial Neoplasms","Breast Cancer","Her2-positive Solid Tumors","Her2-positive Endometrial Cancer","Her2-positive Colorectal Cancer","Gastric Cancer","Non-small Cell Lung Cancer","Colorectal Neoplasms","Her2-positive Gastroesophageal Cancer","Head And Neck Cancer","Her2-positive Breast Cancer"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2330766"],"location":["South Korea","United States","Spain"],"study_start_month":["2"],"keyword":["Stomach Cancer","Gastroesophageal junction","Urothelial Cancer","TLR7/8 agonist","Biliary Tract Cancer","Immunotherapy","Nivolumab","ERBB2","HER2"],"repository":["ECRIN MDR"],"study_status":["Recruiting"],"additional_accession":[]},"is_claimable":false,"name":"A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors","description":"A first-in-human study using BDC-1001 as a single agent and in combination with nivolumab in HER2 expressing advanced malignancies","dates":{"creation":"2020-02-15"},"accession":"2330766","cross_references":{"ClinicalTrials___gov":["NCT04278144"]}}